Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.